* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Sunday, October 5, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    Why Taylor Swift Name-Dropped Elizabeth Taylor in Her New Album – Yahoo

    Here’s Why Taylor Swift Dropped Elizabeth Taylor’s Name in Her New Album

    Al Roker Gives Olivia Dean an Unexpected ‘New Job’ on the ‘Today’ Show – Yahoo

    Al Roker Shocks Olivia Dean with an Exciting New Role on the ‘Today’ Show

    Books about the arts and some haunts for a Denton October – Denton Record-Chronicle

    Uncover Artistic Treasures and Spooky Adventures to Experience in Denton This October

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Toni Braxton Is Turning Her Biggest Hits Into Lifetime Movies – Yahoo

    Toni Braxton Is Turning Her Biggest Hits Into Lifetime Movies – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    What the Recent Price Surge Means for Figure Technology Solutions After SEC Settlement – Yahoo Finance

    What the Recent Price Surge Reveals About Figure Technology Solutions Following SEC Settlement

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    A Tech Expo Shows What China Can Make, but Not Who’ll Buy It All – The New York Times

    Inside China’s Tech Expo: Cutting-Edge Innovations Face Uncertain Demand

    Steampunk Metal Oval Technology Sense Sunglasses Personality Handmade Chain Multicolor Sunglasses UV400 – The San Joaquin Valley Sun

    Steampunk Metal Oval Sunglasses with Handmade Multicolor Chain – Bold UV400 Protection and Unique Style

    STELLA Automotive AI Appoints Fred Seidelman as Chief Technology Officer – Yahoo Finance

    STELLA Automotive AI Appoints Fred Seidelman as New Chief Technology Officer

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    “Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

    Why Taylor Swift Name-Dropped Elizabeth Taylor in Her New Album – Yahoo

    Here’s Why Taylor Swift Dropped Elizabeth Taylor’s Name in Her New Album

    Al Roker Gives Olivia Dean an Unexpected ‘New Job’ on the ‘Today’ Show – Yahoo

    Al Roker Shocks Olivia Dean with an Exciting New Role on the ‘Today’ Show

    Books about the arts and some haunts for a Denton October – Denton Record-Chronicle

    Uncover Artistic Treasures and Spooky Adventures to Experience in Denton This October

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Taylor Swift Releases New Album The Life of a Showgirl : Listen and Read the Full Credits – Yahoo

    Toni Braxton Is Turning Her Biggest Hits Into Lifetime Movies – Yahoo

    Toni Braxton Is Turning Her Biggest Hits Into Lifetime Movies – Yahoo

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    What the Recent Price Surge Means for Figure Technology Solutions After SEC Settlement – Yahoo Finance

    What the Recent Price Surge Reveals About Figure Technology Solutions Following SEC Settlement

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    MAC Brings iPad Technology to Football Sidelines Across All 13 Member Schools – Sports Video Group

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    Technology Is Becoming More Important Than Humans In CX – No Jitter

    A Tech Expo Shows What China Can Make, but Not Who’ll Buy It All – The New York Times

    Inside China’s Tech Expo: Cutting-Edge Innovations Face Uncertain Demand

    Steampunk Metal Oval Technology Sense Sunglasses Personality Handmade Chain Multicolor Sunglasses UV400 – The San Joaquin Valley Sun

    Steampunk Metal Oval Sunglasses with Handmade Multicolor Chain – Bold UV400 Protection and Unique Style

    STELLA Automotive AI Appoints Fred Seidelman as Chief Technology Officer – Yahoo Finance

    STELLA Automotive AI Appoints Fred Seidelman as New Chief Technology Officer

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Controversy Grows as FDA Panel Prepares to Review MDMA Drug

June 4, 2024
in Health
Controversy Grows as FDA Panel Prepares to Review MDMA Drug
Share on FacebookShare on Twitter

A US Food and Drug Administration (FDA) expert panel will meet Tuesday to consider whether to recommend approval of an investigational midomafetamine (MDMA) capsule in combination with psychological intervention for the treatment of posttraumatic stress disorder (PTSD).

But as the drug manufacturer, Lykos Therapeutics, inches closer to a final decision on its new drug application for MDMA-assisted therapy (MDMA-AT), a hail of questions has rained down on the company and its founder about the ethics — and validity — of the two pivotal clinical trials Lykos officials will use to make their case to the FDA’s Psychopharmacologic Drugs Advisory Committee.

An independent medical effectiveness review organization, a “citizen’s petition” to the FDA, and a number of media reports have alleged problems with study design, ethical lapses, a failure to report adverse events, and a raft of concerns from former employees about Rick Doblin, PhD, founder and president Multidisciplinary Association for Psychedelic Studies (MAPS), the nonprofit that launched Lykos. 

An FDA review released Friday raises a number of issues as well, specifically citing functional unblinding in a study that was designed to be a double-blind trial.

The FDA panel will probably hear about these potential problems, but they will also receive testimony from those who champion MDMA as a therapy for PTSD. Several veterans groups have already submitted public comments urging the FDA to approve MDMA-AT. About 7% of veterans will experience PTSD during their lifetime (compared with 6% of the general population), but for some service members this proportion is reportedly as high as 29%. Indeed, the US Department of Veterans Affairs has thrown its weight behind the promise of psychedelics with a request for proposals to study the compounds — including MDMA — in treating PTSD. 

Critics and supporters will converge on the FDA expert panel, which will evaluate the scientific evidence. If approved, MDMA-AT would be the first psychedelic-based therapeutic cleared by the FDA for any condition in the US and the first PTSD medication to receive approval in 24 years. 

Investigator Bias at Play? 

Patented by Merck in 1914, MDMA was never formally studied but was used by psychiatrists and therapists over the years. It became a popular street drug in the 1980s, known as “ecstasy” or “molly.” 

Doblin formed the nonprofit MAPS in 1986 in the wake of a failed legal challenge to stop the Drug Enforcement Administration (DEA) from criminalizing MDMA, which the agency did in 1985 by regulating it as a schedule 1 controlled substance with no accepted medical use. Multiple attempts during the late 1980s to get the FDA to approve formal clinical studies were rejected, but the logjam at the agency began to break in the early 1990s.

MAPS embarked on its clinical studies and became a public benefit company in 2014. In 2017, the FDA designated MDMA-AT as a breakthrough therapy, putting it on a fast track for approval.

In 2021, investigators presented data from the company’s first clinical trial of MDMA-AT, MAPP1, at the European Psychiatric Association congress and published the research in Nature Medicine. The study evaluated 90 patients with PTSD randomly assigned to receive MDMA 80 mg or 120 mg or placebo, followed by three integrative psychotherapy sessions lasting a total of 8 hours. 

Patients could receive a supplemental dose of MDMA after the first dose. The company reported that 82% of patients reported a significant improvement, with more than half saying they no longer had PTSD. Eleven patients (12%) experienced relapse within 12 months.

A few years later, findings from the second trial, MAPP2, were published in Nature Medicine, with similar results in 104 patients.

Lack of Blinding, Unreported Side Effects 

Despite widespread and mostly positive media coverage, the research has had its critics. Chief among them has been the Boston-based independent nonprofit Institute for Clinical and Economic Review (ICER). 

ICER first delved into the trials last fall, David Rind, MD, chief medical officer, told Medscape Medical News. Several experts reported concerns about safety to the organization and claimed that some abuse had occurred during the trials. 

When ICER published its initial report in March, a lack of blinding in the studies was cited as a main issue. MAPP2 researchers reported that 49 of 52 (94%) of people in the MDMA treatment arm “were certain or thought that they received MDMA.”

“Lots of people, including clinical experts, separate from any of the concerned citizens who might have talked to us on this report, raised concerns about bias,” Rind said. And 40% of the trial participants had prior exposure to MDMA, he added.

ICER investigators “heard from multiple experts about the very strong prior beliefs of those involved in the trials (as investigators, therapists and patients) about the benefits of MDMA-AT,” the report claimed.

Lykos waved away bias charges, noting in its response to ICER that it “has consistently sought and received feedback from the FDA throughout the development program.” 

But others also took issue. 

“If you wanted to design the worst possible study in the world, you couldn’t do better,” Allen Frances, MD, professor emeritus of psychiatry and behavioral sciences at Duke University, Durham, North Carolina, told Medscape Medical News. “This is something that should never be considered for FDA approval on the basis of the very limited data available.”

The lack of blinding and “a hot-house therapy environment” are two critical issues, Frances noted.

“There’s no research environment more exotic than this study with two therapists spending 8 hours with a single patient,” he said. Even though no serious adverse events were reported in the studies, “that doesn’t mean that there won’t be problems in the real world,” said Frances.

‘A Therapy Cult’ 

Neşe Devenot, a senior lecturer at Johns Hopkins University’s writing program who had been affiliated with MAPS in the mid-2000s, has been vocal about her concerns.

Lykos has “essentially misrepresented what they’re doing to the FDA,” Devenot told Medscape Medical News. 

In comments that will be submitted to the FDA expert panel on June 4 that Devenot shared with Medscape Medical News, she wrote that MAPS is “a therapy cult” that indoctrinates therapists and participants into “an ideological system of ‘true beliefs.'”

In this model, therapists and clients form unusually close relationships, wrote Devenot, also a research affiliate with the Petrie-Flom Center’s Project on Psychedelics Law and Regulation (POPLAR) at Harvard Law School. She said several episodes of alleged abuse that occurred during trials reflect this therapy model.

“There are several well-documented cases of high-profile therapists who have exploited the increased vulnerability of patients in MDMA therapy, including incidents of entrapment, sexual abuse, and coercive control,” wrote Devenot and more than 70 researchers, clinicians, and others in a citizen’s petition filed with the FDA in late April, calling on the agency to convene an advisory panel to look at the Lykos trials and to have an extended open public hearing. The petition alleged the company committed data fraud and withheld information about adverse events.

Unethical conduct was also cited by the ICER report authors who noted that “sexual boundaries were severely crossed with at least one patient in a phase 2 trial.” 

A 2023 paper in the Canadian Journal of Bioethics described that case, which involved Meaghan Buisson and has since been widely covered in the media. Buisson co-authored a JAMA Psychiatry viewpoint with Devenot that highlighted some other alleged lapses in the MAPS/Lykos trials, and she also signed the citizen’s petition.

Devenot alleges other ethical violations in her comments to the FDA, including that MAPS board chair Vicky Dulai “was part of a community of MAPS associates” that exploited “psychedelics’ known ability to increase vulnerability to ‘love bombing’ and other forms of psychological manipulation” to swindle money from wealthy patients.

The citizen’s petition and ICER investigators also cited a number of reports of severe harms that were not disclosed in the published studies. 

Lykos Responds

In a statement to Medscape Medical News, Lykos denied that anything had gone unreported. “All adverse events and serious adverse events were reported to the FDA,” officials wrote in the statement. 

In addition, in public comments on the ICER report, about 70 of the 109 clinical investigators, clinicians, supervisors, trainers and medical monitors who worked on the MAPS/Lykos studies defended their work. 

“One hundred and nine therapists and principal/co-investigators contributed to the Phase 3 trials of MDMA-AP [MDMA-assisted psychotherapy] for PTSD. To our knowledge, none of them were consulted before the preliminary report was issued,” the investigators wrote in their response. “However, this group is in the strongest position to describe the studies and address accusations related to inappropriate study design and conduct. In the absence of such input, a number of assertions in the ICER report represent hearsay and should be weighted accordingly.”

Participants were “invited to access and process traumatic memories,” which meant that “short-term destabilization” could be expected, they added. They also noted that therapists were guided by the “MAPS Code of Ethics,” which prescribes that practitioners should “respect the inner healing intelligence of participants to guide their experience.” 

ICER said that Lykos never offered direct access to its researchers and that there were reports that patients feared being shunned or denied MDMA in the future if they reported bad outcomes. “This is a particular problem in people receiving MDMA as it makes them particularly suggestible and susceptible to context,” authors of the ICER report wrote.

Opening the Door to Wider Illicit Use?

Frances and Devenot said that FDA approval could open the door to more unprescribed and unsupervised use of MDMA.

Devenot believes that MDMA has potential but said that given that Doblin has been touting MDMA for years, “a lot of people have really taken him at his word and are doing this outside of a formal medical context.” FDA approval would lead people to “think that it’s useful and safe” and would probably increase illegitimate use, she said.

Even if the FDA restricts use of the Lykos therapy to the trial conditions — as the American Psychiatric Association has urged the agency to do — the risk for misuse remains, said Frances. 

If you’re someone who does not meet eligibility requirements or can’t afford the drug, “you’re likely to buy the drug on the street and take it yourself,” said Frances.

The company has not yet determined a price for the treatment, a Lykos spokesperson told Medscape Medical News, but has worked with the American Medical Association to establish a code for the combination therapy, in part to lay the groundwork for insurance coverage. 

Rind wants MDMA-AT to get a thorough vetting by the FDA and its advisers. “I’m hoping that the FDA looks carefully at the evidence in ways that we certainly were unable to do,” he said.

The FDA is due to make a decision on the MDMA-AT’s fate by August 11. If the drug is approved, the DEA would still have to reschedule the drug so that physicians can prescribe it. 

The agency is under no legal obligation to change MDMA’s status unless it is directed to do so by the US Department of Health and Human Services. The DEA would have 90 days to act on the request, according to an analysis from the Harvard Law School’s Petrie-Flom Center. A similar path was followed for the cannabis-based pharmaceutical Epidiolex. 

Lykos said it would make its therapy available in 2025 if it is approved and the DEA reschedules MDMA.

Alicia Ault is a Saint Petersburg, Florida–based freelance journalist whose work has appeared in publications including JAMA and Smithsonian.com. You can find her on X @aliciaault.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Medscape – https://www.medscape.com/viewarticle/controversy-grows-fda-panel-prepares-review-mdma-drug-2024a1000adh

Tags: controversygrowshealth
Previous Post

Does Palliative Care via Telehealth Work in Advanced Cancer?

Next Post

High Rate of Surgery in Patients With Crohn’s Disease

Magdeleine Vallieres shows off her world championship stripes – EF Pro Cycling

Magdeleine Vallieres shows off her world championship stripes – EF Pro Cycling

October 5, 2025
Splurging? In This Economy? Here’s How to Do It Right. – The New York Times

Splurging? In This Economy? Here’s How to Do It Right. – The New York Times

October 5, 2025
“Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

“Reba” cast, then and now: See the stars 24 years later (and who’s reunited for another show) – Yahoo

October 5, 2025
How the government shutdown is hitting the health care system – and what the battle over ACA subsidies means – The Conversation

How the Government Shutdown Is Disrupting Health Care and What the Battle Over ACA Subsidies Means for You

October 5, 2025
Politics | Shutdown Showdown and More Court Battles – “The Sunday Political Brunch” – GoLocalProv

Shutdown Showdown and Intense Court Battles: Inside This Week’s Political Drama

October 5, 2025
First Record of Mating Involving a Melanistic Jaguar (Panthera onca) in the Wild: Novel Behavioural Insights Into Colour Morphs and Captive‐Wild Comparisons – Luypaert – 2025 – Ecology and Evolution – Wiley Online Library

First Record of Mating Involving a Melanistic Jaguar (Panthera onca) in the Wild: Novel Behavioural Insights Into Colour Morphs and Captive‐Wild Comparisons – Luypaert – 2025 – Ecology and Evolution – Wiley Online Library

October 5, 2025
Multi-generational vulture nests hold 700 years of human artifacts – Popular Science

Multi-generational vulture nests hold 700 years of human artifacts – Popular Science

October 5, 2025
Chinese tech company develops creepy ultra-lifelike robot face — watch it blink, twitch and nod – Live Science

Chinese tech company develops creepy ultra-lifelike robot face — watch it blink, twitch and nod – Live Science

October 5, 2025
FSE Lifestyle Services (HKG:331) Has Announced That Its Dividend Will Be Reduced To HK$0.185 – simplywall.st

FSE Lifestyle Services (HKG:331) Has Announced That Its Dividend Will Be Reduced To HK$0.185 – simplywall.st

October 5, 2025
Irrigation technology adapts to water restrictions – Farm Progress

Innovative Irrigation Technologies Transform Farming Amid Water Restrictions

October 5, 2025

Categories

Archives

October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Sep    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (852)
  • Economy (873)
  • Entertainment (21,747)
  • General (17,424)
  • Health (9,915)
  • Lifestyle (885)
  • News (22,149)
  • People (874)
  • Politics (884)
  • Science (16,083)
  • Sports (21,373)
  • Technology (15,854)
  • World (856)

Recent News

Magdeleine Vallieres shows off her world championship stripes – EF Pro Cycling

Magdeleine Vallieres shows off her world championship stripes – EF Pro Cycling

October 5, 2025
Splurging? In This Economy? Here’s How to Do It Right. – The New York Times

Splurging? In This Economy? Here’s How to Do It Right. – The New York Times

October 5, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version